Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
KOD · Why this verdict
Why Kodiak Sciences (KOD) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus places fair value roughly 60% above the current share price, reflecting expectations that pipeline milestones will be delivered over the coming quarters. Sentiment | Price approaches the consensus target of approximately $54 within 12 months as pipeline catalysts materialize. | →Stable |
| CounterNegative free cash flow means each quarter of losses depends on external capital; analyst targets built on clinical success assumptions can compress sharply if trial readouts disappoint, eliminating the upside case. | ||
Free cash flow is negative and no competitive moat has been identified; the business is not self-funding, and each loss quarter reduces the balance sheet buffer available to support ongoing operations. Quality | Free cash flow turns positive for 2 consecutive quarters, signaling the business is approaching self-sufficiency. | →Stable |
| CounterThe current ratio of 9.5 indicates substantial near-term liquidity, limiting immediate solvency risk and providing runway for the company to pursue catalysts before additional capital is needed. | ||
Short interest at 26% of float reflects deep market skepticism; combined with beta above 2 and implied volatility of 139%, the stock is positioned for extreme binary moves in either direction around any meaningful catalyst. Risk | Short interest falls below 12% of float over the next 12 months as near-term uncertainty resolves. | →Stable |
| CounterHeavy short positioning can itself become the fuel for a violent upside move if a positive catalyst forces covering — the bearish consensus does not guarantee downside and could amplify any positive surprise. | ||
Rising on-balance volume and the stock's position above its 200-day moving average indicate buyers are absorbing supply at current levels despite the quality concerns, providing a degree of technical support. Momentum | On-balance volume trends higher and the stock holds above the 200-day moving average for 2 consecutive quarters. | →Stable |
| CounterTechnical accumulation can be overwhelmed by a single disappointing clinical or financial result; a negative catalyst may rapidly reverse both the OBV trend and the price relationship to the 200-day average. | ||
Analyst consensus places fair value roughly 60% above the current share price, reflecting expectations that pipeline milestones will be delivered over the coming quarters.
→StableSentiment
- Expectation
- Price approaches the consensus target of approximately $54 within 12 months as pipeline catalysts materialize.
CounterNegative free cash flow means each quarter of losses depends on external capital; analyst targets built on clinical success assumptions can compress sharply if trial readouts disappoint, eliminating the upside case.
Free cash flow is negative and no competitive moat has been identified; the business is not self-funding, and each loss quarter reduces the balance sheet buffer available to support ongoing operations.
→StableQuality
- Expectation
- Free cash flow turns positive for 2 consecutive quarters, signaling the business is approaching self-sufficiency.
CounterThe current ratio of 9.5 indicates substantial near-term liquidity, limiting immediate solvency risk and providing runway for the company to pursue catalysts before additional capital is needed.
Short interest at 26% of float reflects deep market skepticism; combined with beta above 2 and implied volatility of 139%, the stock is positioned for extreme binary moves in either direction around any meaningful catalyst.
→StableRisk
- Expectation
- Short interest falls below 12% of float over the next 12 months as near-term uncertainty resolves.
CounterHeavy short positioning can itself become the fuel for a violent upside move if a positive catalyst forces covering — the bearish consensus does not guarantee downside and could amplify any positive surprise.
Rising on-balance volume and the stock's position above its 200-day moving average indicate buyers are absorbing supply at current levels despite the quality concerns, providing a degree of technical support.
→StableMomentum
- Expectation
- On-balance volume trends higher and the stock holds above the 200-day moving average for 2 consecutive quarters.
CounterTechnical accumulation can be overwhelmed by a single disappointing clinical or financial result; a negative catalyst may rapidly reverse both the OBV trend and the price relationship to the 200-day average.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Kodiak Sciences presents a speculative setup: analyst consensus implies roughly 60% upside and technical accumulation is underway, but negative free cash flow, the absence of a competitive moat, and 26% short interest disqualify the stock at current quality levels — patience is warranted until the business demonstrates a path to self-sufficiency.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.5 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.8 |
| erm sentiment | 5.9 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 63%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $1,023,009 (0.042% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.5 |
| support resistance | 1.5 |
| 52w position | 6.1 |
| gap | 5.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.8 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 2.7 |
| debt equity | 8.0 |
- ▸High short interest justified: 27%
- ▸High IV: 105%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 2.3 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.6>=5.5
- ASYMMETRY:2.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.76
Upside
+41.5%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 64, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Momentum at 7.6; the weakest are Quality at 2.2, Peer rank at 2.5, and Risk (lower is worse) at 3.1. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.76 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Implied Large Upside
Trip ifAnalyst consensus target falls below $40 for 2 consecutive months, compressing implied upside to less than 17% from the current price.
- P2Cash Burning No Competitive Moat
Trip ifFree cash flow rises above $0 for 2 consecutive quarters.
- P3High Short Interest Binary Risk
Trip ifShort interest falls below 10% of float for 2 consecutive reporting periods.
- P4Technical Accumulation Provides Support
Trip ifPrice closes below $29 for 3 consecutive weeks, signaling a breakdown of the technical accumulation zone.